Jang Mi Han
Overview
Explore the profile of Jang Mi Han including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han J, Kim S, Kim H, Cho H, Jung H
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298389
Non-small cell lung cancer (NSCLC) is a fatal malignant tumor with a high mortality rate. Cancer stem cells (CSCs) play pivotal roles in tumor initiation and progression, treatment resistance, and...
2.
Han J, Jung H
Molecules
. 2022 Nov;
27(22).
PMID: 36432068
Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. Relapse is frequent and rapid due to glioblastoma stem-like cells (GSCs) that induce tumor initiation, drug resistance, high cancer...
3.
Han J, Jung H
Int J Mol Sci
. 2022 Aug;
23(16).
PMID: 36012604
Cyclophilin A (CypA), which has peptidyl-prolyl isomerase (PPIase) activity, regulates multiple functions of cells by binding to its extracellular receptor CD147. The CypA/CD147 interaction plays a crucial role in the...
4.
Han J, Kim Y, Jung H
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267623
Glioblastoma stem-like cells (GSCs) drive tumor initiation, cancer invasion, immune evasion, and therapeutic resistance and are thus a key therapeutic target for improving treatment for glioblastoma multiforme (GBM). We previously...
5.
Kim Y, Han J, Jung H
Biochem Biophys Res Commun
. 2021 Jun;
566:129-134.
PMID: 34119825
Glioblastoma (GBM) is one of the most malignant brain tumors and requires the formation of new blood vessels, called angiogenesis, for its growth and metastasis. Several proangiogenic factors, including vascular...
6.
Han J, Kim H, Jung H
Int J Mol Sci
. 2021 Apr;
22(8).
PMID: 33924032
Leukemia is a type of blood cancer caused by the rapid proliferation of abnormal white blood cells. Currently, several treatment options, including chemotherapy, radiation therapy, and bone marrow transplantation, are...
7.
Han J, Sohng J, Lee W, Oh T, Jung H
Int J Mol Sci
. 2021 Apr;
22(5).
PMID: 33804393
We recently discovered a novel nargenicin A1 analog, 23-demethyl 8,13-deoxynargenicin (compound 9), with potential anti-cancer and anti-angiogenic activities against human gastric adenocarcinoma (AGS) cells. To identify the key molecular targets...
8.
Choi Y, Han J, Kang Y, Jung H
Mol Med Rep
. 2020 Nov;
23(1).
PMID: 33236129
Cervical cancer is the second most common cancer among women worldwide. However, chemotherapies for this cancer often cause many side effects and chemoresistance. Markovich peel (CECU) has been used as...
9.
Han J, Choi Y, Dhakal D, Sohng J, Jung H
Biomedicines
. 2020 Aug;
8(8).
PMID: 32751120
Targeting angiogenesis is an attractive strategy for the treatment of angiogenesis-related diseases, including cancer. We previously identified 23-demethyl 8,13-deoxynargenicin (compound ) as a novel nargenicin A1 analog with potential anticancer...
10.
Nguyen T, Han J, Jung H, Pandey R, Park Y, Sohng J
J Ind Microbiol Biotechnol
. 2020 Jun;
47(6-7):537-542.
PMID: 32588231
Alizarin has been reported to have an antigenotoxic activity along with an inhibitory effect on the tumor cell growth of human colon carcinoma cells. Alizarin was biotransformed into an O-methoxide...